Pharma Focus Asia

Interactome Overlap Between Risk Genes of Epilepsy and Targets of Anti-epileptic

Yu-Qin Lv, Xing Wang, Yu-Zhuang Jiao, Yan-Hua Wang, Na Wang, Lei Gao , Jing-Jun Zhang

Abstract

Aanti-epileptic drugs have been used for treating epilepsy for decades, meanwhile, more than one hundred genes have been identified to be associated with risk of epilepsy; however, the interaction mechanism between anti-epileptic drugs and risk genes of epilepsy was still not clearly understood. In this study, we systematically explored the interaction of epilepsy risk genes and anti-epileptic drug targets through a network-based approach.

Introduction

Epilepsy is a collective term for a group of syndromes caused by abnormal discharges of the nervous system, and can cause varying degrees of damage to behavior, cognition, and memory. Previous studies have shown that epilepsy genetic factors contributed a lot to the pathogenesis of epilepsy.

Materials and Methods:

1. Identification of risk genes of epilepsy

We obtained risk genes of epilepsy identified by both common variants and rare variants, of which common variants are extracted from the largest trans-ethnic meta-analyses of genome-wide association studies currently.

2. Identification of anti-epileptic drugs targets

DrugBank (https://go.drugbank.com/) is a web-based database containing comprehensive molecular information about drugs, their mechanisms of action, interactions, and their targets.

Discussion

Epilepsy is a widespread chronic nervous system disease, which affects about 70 million people all over the world, during this decade, with the development of sequencing technology, hundreds of risk genes associated with epilepsy have been identified by genetic studies, GWAS, as well as sequencing.

Citation: Lv Y-Q, Wang X, Jiao Y-Z, Wang Y-H, Wang N, Gao L, et al. (2022) Interactome overlap between risk genes of epilepsy and targets of anti-epileptic drugs. PLoS ONE 17(8): e0272428. https://doi.org/10.1371/journal.pone.0272428

Editor: Nien-Pei Tsai, University of Illinois at Urbana-Champaign, UNITED STATES

Received: February 28, 2022; Accepted: July 19, 2022; Published: August 25, 2022.

Copyright: © 2022 Lv et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: DrugBank:https://go.drugbank.com/; Interactome data and Network Calculator: https://github.com/Haoxiang-Qi/Network-Calculator.git; EWCE and KI dataset: https://github.com/NathanSkene/EWCE; http://www.hjerling-leffler-lab.org/data/scz_singlecell/.

Funding: This research was supported by Medical Health Science and Technology Project of Shandong Provincial Health Commission (2019WS391), Academic Promotion Program of Shandong First Medical University (2019QL013), National Natural Science Foundation of China (32000477), Shandong provincial Natural Science Foundation (ZR2020MC061), Science and Technology Program of Colleges and Universities in Shandong Province(J15LL07) and the planned project of Tai'an Science and Technology Bureau(2017NS0248).


Competing interests: The authors have declared that no competing interests exist.

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024